{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:26:25Z","timestamp":1761182785056,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2003]]},"DOI":"10.1007\/s10156-002-0212-8","type":"journal-article","created":{"date-parts":[[2003,12,10]],"date-time":"2003-12-10T18:53:01Z","timestamp":1071082381000},"page":"12-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae"],"prefix":"10.1016","volume":"9","author":[{"given":"Arvind M.","family":"Dhople","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s10156-002-0212-8_bib0005","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2307\/4584691","article-title":"The promin treatment of leprosy: a progress report","volume":"58","author":"Faget","year":"1943","journal-title":"Public Health Rep"},{"key":"10.1007\/s10156-002-0212-8_bib0010","first-page":"4","article-title":"Two and a half years experimental work on the sulfone groups of drugs","volume":"20","author":"Cochrane","year":"1949","journal-title":"Lepr Rev"},{"key":"10.1007\/s10156-002-0212-8_bib0015","first-page":"6","article-title":"\u2018B663\u2019 in the treatment of leprosy: preliminary report of a pilot trial","volume":"33","author":"Brown","year":"1962","journal-title":"Lepr Rev"},{"key":"10.1007\/s10156-002-0212-8_bib0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/bmj.1.5688.89","article-title":"Experimental and clinical studies on rifampicin in treatment of leprosy","volume":"1","author":"Rees","year":"1970","journal-title":"BMJ"},{"key":"10.1007\/s10156-002-0212-8_bib0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(64)92482-1","article-title":"Sulphone resistance in leprosy: an experimental and clinical study","volume":"II","author":"Petit","year":"1964","journal-title":"Lancet"},{"key":"10.1007\/s10156-002-0212-8_bib0030","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0140-6736(76)92071-7","article-title":"Rifampin-resistant leprosy","volume":"II","author":"Jacobson","year":"1976","journal-title":"Lancet"},{"key":"10.1007\/s10156-002-0212-8_bib0035","first-page":"139","article-title":"Clofazimine-resistant leprosy \u2013 a case report","volume":"50","author":"Worndorff-can Diepen","year":"1982","journal-title":"Int J Lepr"},{"first-page":"675","year":"1982","series-title":"Chemotherapy of leprosy for control programs","key":"10.1007\/s10156-002-0212-8_bib0040"},{"key":"10.1007\/s10156-002-0212-8_bib0045","first-page":"114","article-title":"Report of the first meeting of the WHO Working Group in Leprosy Control","volume":"60","year":"1992","journal-title":"Int J Lepr"},{"key":"10.1007\/s10156-002-0212-8_bib0050","first-page":"33","article-title":"Remaining challenges towards the elimination of leprosy","volume":"72","year":"2000","journal-title":"Indian J Lepr"},{"key":"10.1007\/s10156-002-0212-8_bib0055","first-page":"265","article-title":"Drug resistance in leprosy","volume":"56","author":"Ji","year":"1985","journal-title":"Lepr Rev"},{"key":"10.1007\/s10156-002-0212-8_bib0060","first-page":"379","article-title":"Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy","volume":"67","author":"Chen","year":"1999","journal-title":"Int J Lepr"},{"key":"10.1007\/s10156-002-0212-8_bib0065","first-page":"272","article-title":"Relapses as histoid leprosy after receiving multidrug therapy: a report of three cases","volume":"68","author":"Shaw","year":"2000","journal-title":"Int J Lepr"},{"key":"10.1007\/s10156-002-0212-8_bib0070","first-page":"384","article-title":"In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae","volume":"43","author":"Dhople","year":"1993","journal-title":"Arzneim-Forsch\/Drug Res"},{"key":"10.1007\/s10156-002-0212-8_bib0075","first-page":"563","article-title":"In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin","volume":"44","author":"Dhople","year":"1994","journal-title":"Arzneim-Forsch\/Drug Res"},{"key":"10.1007\/s10156-002-0212-8_bib0080","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.39.9.2116","article-title":"In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae","volume":"39","author":"Dhople","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-002-0212-8_bib0085","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/AAC.36.7.1491","article-title":"Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates","volume":"36","author":"Sato","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-002-0212-8_bib0090","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/AAC.38.12.2877","article-title":"In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a","volume":"38","author":"Sato","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-002-0212-8_bib0095","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.43.12.3001","article-title":"Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-5869a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"43","author":"Tomioka","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-002-0212-8_bib0100","unstructured":"World Health Organization. Purification of M. leprae. Annex 4 of report of the fifth meeting of the SWG on the immunology of leprosy, Geneva, 24-26 June 1980. WHO Document No. TDR\/IMMLEP-SWG (5) 80.3."},{"key":"10.1007\/s10156-002-0212-8_bib0105","first-page":"156","article-title":"A guide to the counting of mycobacteria in clinical and experimental materials","volume":"32","author":"Hanks","year":"1964","journal-title":"Int J Lepr"},{"key":"10.1007\/s10156-002-0212-8_bib0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0769-2609(88)90006-3","article-title":"Limited in vitro multiplication of Mycobacterium leprae","volume":"139","author":"Dhople","year":"1988","journal-title":"Ann Inst Pasteur Microbiol"},{"key":"10.1007\/s10156-002-0212-8_bib0115","first-page":"66","article-title":"An in vitro culture method for screening new drugs against Mycobacterium leprae","volume":"62","author":"Dhople","year":"1990","journal-title":"Indian J Lepr"},{"key":"10.1007\/s10156-002-0212-8_bib0120","first-page":"807","article-title":"An in vitro system using adenosine triphosphate and 3H-thymidine to determine drug sensitivity of Mycobacterium leprae","volume":"14","author":"Dhople","year":"1986","journal-title":"IRCS Med Sci"},{"key":"10.1007\/s10156-002-0212-8_bib0125","first-page":"149","article-title":"Limited in vitro multiplication of Mycobacterium leprae: application to screening potential antileprosy compounds","volume":"57","author":"Dhople","year":"1986","journal-title":"Lepr Rev"},{"key":"10.1007\/s10156-002-0212-8_bib0130","first-page":"187","article-title":"Autoradiographic and metabolic studies of Mycobacterium leprae","volume":"49","author":"Khanolkar","year":"1978","journal-title":"Lepr Rev"},{"key":"10.1007\/s10156-002-0212-8_bib0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/35.4.463","article-title":"In vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae","volume":"35","author":"Dhople","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s10156-002-0212-8_bib0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1126\/science.327548","article-title":"In vitro growth of Mycobacterium lepraemurium, an obligate intracellular microbe","volume":"197","author":"Dhople","year":"1977","journal-title":"Science"},{"key":"10.1007\/s10156-002-0212-8_bib0145","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/BF02013394","article-title":"Evaluation of a bioluminescence assay for rapid antimicrobial susceptibility testing of mycobacteria","volume":"4","author":"Beckers","year":"1985","journal-title":"Eur J Clin Microbiol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X04711587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X04711587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10156-002-0212-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:43:54Z","timestamp":1761158634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X04711587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003]]}},"alternative-id":["S1341321X04711587"],"URL":"https:\/\/doi.org\/10.1007\/s10156-002-0212-8","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2003]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-002-0212-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}